DECREASED PLASMINOGEN-ACTIVATOR INHIBITOR-1 ACTIVITY IN NEWLY-DIAGNOSED TYPE-2 DIABETIC-PATIENTS FOLLOWING DIETARY MODIFICATION

被引:17
作者
BAHRU, Y [1 ]
KESTEVEN, P [1 ]
ALBERTI, KGMM [1 ]
WALKER, M [1 ]
机构
[1] UNIV NEWCASTLE UPON TYNE,DEPT MED,FRAMLINGTON PL,NEWCASTLE TYNE NE2 4HH,ENGLAND
关键词
TYPE-2; DIABETES; PLASMINOGEN ACTIVATOR INHIBITOR-1; COAGULATION FACTORS; DIET TREATMENT;
D O I
10.1111/j.1464-5491.1993.tb00169.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Increased plasminogen activator inhibitor-1 (PAI-1) activity has been reported in Type 2 (non-insulin-dependent) diabetes and is a recognized risk factor for coronary artery disease. Fourteen newly diagnosed Type 2 diabetic patients were studied before and 3 months after standard clinical dietary modification. To -assess the effect of improved metabolic control on PAI-1 activity, nine Type 2 diabetic patients established on diet therapy and with previous,stable glycaemic control served as controls. In the newly diagnosed patients diet therapy resulted in a significant decrease in HbA1c levels (8.3 +/- 0.5 vs 5.2 +/- 0.3 % (mean +/- SEM); p < 0.001), and this was accompanied by a fall in fibrinogen (4.3 +/- 0.3 vs 3.0 +/- 0.2 g.l-1; p < 0.01) concentration, and PAI-1 (18.7 +/- 2.3 vs 12.2 +/- 0.9 arbitrary units ml-1; p < 0.02) and factor VIII (147 +/- 17 vs 115 +/- 13 %; p < 0.01) activities. PAI-1 activity was correlated with triglyceride levels at the first assessment in the newly diagnosed patients (r = 0.66; p < 0.01), and this was the only independent association by multiple regression analysis when all patients (n = 23) were considered (r = 0.62; p < 0.002). However, there was no association between the changes in PAI-1 activity and the changes in HbA1c BMI, and serum triglyceride levels following treatment in the newly diagnosed patients. Serum triglyceride concentrations, HBA1c, PAI-1 activity, and the coagulation factors remained unchanged in the control group over the same treatment period. In conclusion, the introduction of conventional diet therapy in newly diagnosed Type 2 diabetic patients was accompanied by a significant improvement in circulating PAI-1 activity, but this could not be related to changes in the common indices of metabolic control.
引用
收藏
页码:802 / 806
页数:5
相关论文
共 31 条
[1]  
Garcia MJ, McNamara PM, Gordon T., Kannell WB, Morbidity and mortality in diabetics in the Framingham population, Diabetes, 23, pp. 105-111, (1974)
[2]  
Paton RC, Kernoff PBA, Wales JK, McNicol GP, Effects of diet and gliclazide on the haemostatic system of non‐insulin‐dependent diabetics, Br Med J, 283, pp. 1018-1020, (1981)
[3]  
Schneider SH, Kim HC, Khachadurian AK, Ruderman NB, Impaired fibrinolytic response to exercise in Type II diabetes: effects of exercise and physical training, Metabolism, 37, pp. 924-929, (1988)
[4]  
Kruithof EKQ, Tran-Thang C., Ransijn A., Bachmann F., Demonstration of a fast‐acting inhibitor of plasminogen activators in human plasma, Blood, 64, pp. 907-913, (1984)
[5]  
Wiman B., Hamsten A., The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease, Semin Thromb Hemost, 16, pp. 207-216, (1990)
[6]  
Hamsten A., Blomback M., Wiman B., Svensson J., Szamosi A., de Faire U., Et al., Haemostatic function in myocardial infarction, Br Heart J, 55, pp. 58-66, (1986)
[7]  
Aznar J., Estelles A., Tormo G., Sapena P., Tormo V., Blanch S., Et al., Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease, Br Heart J, 59, pp. 535-541, (1988)
[8]  
Olofsson BO, Dahlen G., Nilsson TK, Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease, Eur Heart J, 10, pp. 77-82, (1989)
[9]  
Auwerx J., Bouillon R., Collen D., Geboers J., Tissue‐type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus, Arteriosclerosis, 8, pp. 68-72, (1988)
[10]  
Walmsley D., Hampton KK, Grant PJ, Contrasting fibrinolytic responses in Type 1 (insulin‐dependent) and Type 2 (non‐insulin‐dependent) diabetes, Diabetic Med, 8, pp. 954-959, (1991)